LXEO
HealthcareLexeo Therapeutics, Inc. Common Stock · Biotechnology · $410M
What is Lexeo Therapeutics, Inc. Common Stock?
Lexeo Therapeutics is a clinical-stage genetic medicine company based in New York City, focused on developing gene therapies for serious hereditary and acquired diseases. The company targets conditions affecting the heart and brain with a pipeline of AAVrh10-based candidates.
Lexeo Therapeutics develops gene therapy candidates designed to address the underlying genetic causes of rare diseases. Its pipeline spans two primary areas: cardiac conditions — including Friedreich's ataxia cardiomyopathy, arrhythmogenic cardiomyopathy, DSP cardiomyopathy, and HCM caused by TNNI3 mutations — and neurological conditions, including APOE4-related Alzheimer's disease and CLN2 Batten disease. The company generates no product revenue at this stage, relying on capital markets to fund ongoing clinical development.
Lexeo Therapeutics was incorporated in 2017 and is headquartered in New York City, New York.
- LX2006 — gene therapy candidate for Friedreich's ataxia cardiomyopathy
- LX2020 — candidate targeting arrhythmogenic cardiomyopathy
- LX1001 — AAVrh10-based candidate for APOE4 homozygous Alzheimer's disease
- LX1004 — candidate for CLN2 Batten disease
- LX2021 / LX2022 — candidates for DSP and HCM cardiomyopathies
Is LXEO a Good Stock to Buy?
UQS Score rates LXEO as Poor overall, reflecting the realities of a pre-revenue, clinical-stage biotech.
The one relative bright spot in LXEO's profile is its Risk pillar, which scores Good — suggesting the company's balance sheet and near-term financial risk are managed more carefully than many peers at a similar development stage. This is meaningful for a company that depends entirely on external funding to advance its pipeline.
Quality, Moat, and Growth all register as Weak, which is expected for a company with no approved products and no commercial revenue. Valuation is rated Elevated, meaning the market is pricing in significant future success that has yet to be demonstrated clinically.
See the complete pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does LXEO pay dividends?
No — Lexeo Therapeutics, Inc. Common Stock does not currently pay a dividend.
Lexeo Therapeutics does not pay a dividend. As a clinical-stage company with no product revenue, all available capital is directed toward advancing its gene therapy pipeline through clinical trials. Income-focused investors should not expect distributions from LXEO in the foreseeable future.
When does LXEO report earnings?
Lexeo Therapeutics reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue company, quarterly reports focus primarily on cash runway, research and development expenditure, and clinical program updates rather than traditional revenue or profit metrics. Pipeline milestones and trial readouts tend to be the most market-moving disclosures.
For the most recent quarter's results and upcoming reporting dates, visit Lexeo Therapeutics' investor relations page directly.
LXEO Price History
-50.6% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Lexeo Therapeutics, Inc. Common Stock?
Based on Lexeo Therapeutics, Inc. Common Stock's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
LXEO Long-term Outlook
With Growth and Quality pillars both rated Weak, LXEO's near-term fundamental outlook is heavily dependent on clinical trial outcomes rather than financial momentum. The Good Risk rating provides some reassurance that the company is not in immediate financial distress, but the Elevated Valuation pillar signals that the current market price already reflects optimistic assumptions about pipeline success. Progress in any of its cardiac or neurological programs could shift the fundamental picture materially.
Growth drivers
- Positive clinical data readouts from the LX2006 or LX1001 programs
- Expansion of the gene therapy market for rare cardiac and neurological diseases
- Potential partnership or licensing deals that validate pipeline assets
Key risks
- Clinical trial failure or delays across any pipeline candidate
- Elevated valuation leaves little margin of safety if milestones slip
- Ongoing reliance on capital raises to fund operations with no revenue offset
LXEO vs Peers
Lexeo Therapeutics operates in a competitive rare-disease and genetic medicine landscape alongside other clinical and commercial-stage biotechs.
Contineum focuses on central nervous system and inflammatory diseases, giving it a different therapeutic focus than Lexeo's cardiac and neurological gene therapy approach.
MiMedx is a commercial-stage regenerative medicine company, contrasting with Lexeo's entirely pre-revenue, clinical-stage profile.
DBV Technologies develops epicutaneous immunotherapy for food allergies, representing a distinct modality and disease focus from Lexeo's AAV-based gene therapies.
Frequently Asked Questions
What does Lexeo Therapeutics do?
Lexeo Therapeutics is a clinical-stage genetic medicine company developing gene therapies for rare hereditary and acquired diseases. Its pipeline targets serious cardiac conditions — such as Friedreich's ataxia cardiomyopathy — and neurological diseases, including APOE4-related Alzheimer's disease and CLN2 Batten disease. The company has not yet received regulatory approval for any product.
Does LXEO pay dividends?
No, Lexeo Therapeutics does not pay a dividend. The company is pre-revenue and uses its capital to fund clinical research. Investors seeking income should look elsewhere, as dividend payments are not expected at this stage of development.
When does LXEO report earnings?
Lexeo Therapeutics follows a standard quarterly reporting cadence for US-listed companies. Because it has no product revenue, reports focus on cash position and pipeline updates. Check the company's investor relations page for the most current schedule.
Is LXEO a good stock to buy?
UQS Score rates LXEO as Poor overall, driven by Weak scores across Quality, Moat, and Growth pillars. The Good Risk rating is a relative positive, but the Elevated Valuation pillar suggests the market has already priced in meaningful pipeline success. Investors should weigh clinical-stage risk carefully before making any decision.
Is LXEO overvalued?
UQS Score's Valuation pillar for LXEO is rated Elevated. For a company with no approved products or commercial revenue, the current market pricing implies significant optimism about future clinical outcomes. That gap between current fundamentals and implied expectations is a key consideration for prospective investors.
How does LXEO compare to its competitors?
Compared to peers like MiMedx — which already generates commercial revenue — Lexeo is at an earlier and riskier stage of development. Against other clinical-stage biotechs such as Contineum Therapeutics and DBV Technologies, the key differentiator is Lexeo's specific focus on AAV-based gene therapy for cardiac and neurological rare diseases.
What is LXEO's market cap bracket?
Lexeo Therapeutics is classified as a small-cap company. This places it in a segment of the market that typically carries higher volatility and liquidity risk compared to mid- or large-cap peers, which is consistent with its clinical-stage status.
Who founded Lexeo Therapeutics?
Lexeo Therapeutics was incorporated in 2017 and is based in New York City. Detailed founding history and leadership background are publicly available through the company's official website and SEC filings.
Is LXEO a long-term quality investment?
As a long-term quality indicator, UQS Score currently rates LXEO as Poor. The Weak Quality and Moat pillars reflect the absence of durable competitive advantages or proven financial performance at this stage. Long-term quality potential depends almost entirely on whether its pipeline candidates achieve clinical and regulatory success.
What is the main competitive advantage of Lexeo Therapeutics?
Lexeo's primary differentiator is its focus on AAVrh10-based gene therapy delivery across both cardiac and neurological rare diseases — a dual-platform approach that few small-cap biotechs pursue simultaneously. However, the Moat pillar is currently rated Weak, reflecting that no approved product yet anchors a durable competitive position.
What sector does LXEO belong to?
Lexeo Therapeutics operates in the Healthcare sector, specifically within the clinical-stage biotechnology and genetic medicine space. Investors can explore other [healthcare sector stocks](/sector/healthcare) rated by UQS Score for broader context.
Is LXEO a growth stock or value stock?
Based on UQS pillar labels, LXEO does not fit neatly into either category in a traditional sense. Its Growth pillar is rated Weak — reflecting no revenue growth to measure — while its Valuation pillar is Elevated, ruling out a value characterization. It is best understood as a speculative clinical-stage biotech.
Unlock Full LXEO Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access underlying financial metrics and trend data
- ✓Compare LXEO against rated sector peers
- ✓See risk and valuation flags in detail
- ✓Track pipeline-stage companies across Healthcare
- ✓Get the full analyst view available to Pro members
Pro Analysis
LXEO — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | 16.2 | 0.0 | 9.0 | 18.5 | 68.3 | 0.0 | -1.0 |
| Apr 22, 2026 | 17.2 | 0.0 | 9.0 | 18.5 | 75.3 | 0.0 | -1.0 |
| Apr 2, 2026 | 18.2 | 0.0 | 9.0 | 23.1 | 75.3 | 0.0 | — |
LXEO — Pillar Breakdown
Quality
— 0.0/100 (25%)Lexeo Therapeutics, Inc. Common Stock currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 18.5/100 (20%)Lexeo Therapeutics, Inc. Common Stock faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 68.3/100 (15%)Lexeo Therapeutics, Inc. Common Stock maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Lexeo Therapeutics, Inc. Common Stock appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 9/100 (25%)Lexeo Therapeutics, Inc. Common Stock operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for LXEO.
Score Composition
Financial Data
More Stock Analysis
How is the LXEO UQS Score Calculated?
The UQS (Unified Quality Score) for Lexeo Therapeutics, Inc. Common Stock is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Lexeo Therapeutics, Inc. Common Stock's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Lexeo Therapeutics, Inc. Common Stock is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.